Prid delta Leggangainnlegg 1,55 g Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

prid delta leggangainnlegg 1,55 g

ceva santé animale* - progesteronum inn - leggangainnlegg - 1,55 g

Bemfola Европейский союз - исландский - EMA (European Medicines Agency)

bemfola

gedeon richter plc. - follitrópín alfa - anovulation - hormón kynlíf og stillum kynfæri - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. Í klínískum raunir þessar sjúklinga sem voru skilgreind af innræn blóðvatn ace stigi < 1. 2 ae / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Menopur Stungulyfsstofn og leysir, lausn 1200 a.e. Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

menopur stungulyfsstofn og leysir, lausn 1200 a.e.

ferring lægemidler a/s - menotropinum - stungulyfsstofn og leysir, lausn - 1200 a.e.

Menopur Stungulyfsstofn og leysir, lausn 600 a.e. Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

menopur stungulyfsstofn og leysir, lausn 600 a.e.

ferring lægemidler a/s - menotropinum - stungulyfsstofn og leysir, lausn - 600 a.e.

Menopur Stungulyfsstofn og leysir, lausn 75 a.e. Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

menopur stungulyfsstofn og leysir, lausn 75 a.e.

ferring lægemidler a/s - menotrophin hp - stungulyfsstofn og leysir, lausn - 75 a.e.

Menopur Stungulyf, lausn í áfylltum lyfjapenna 1200 a.e. Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

menopur stungulyf, lausn í áfylltum lyfjapenna 1200 a.e.

ferring lægemidler a/s - menotropinum - stungulyf, lausn í áfylltum lyfjapenna - 1200 a.e.

Menopur Stungulyf, lausn í áfylltum lyfjapenna 600 a.e. Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

menopur stungulyf, lausn í áfylltum lyfjapenna 600 a.e.

ferring lægemidler a/s - menotropinum - stungulyf, lausn í áfylltum lyfjapenna - 600 a.e.

Improvac Европейский союз - исландский - EMA (European Medicines Agency)

improvac

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - Ónæmissjúkdómar fyrir suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. einnig er hægt að minnka annan lykilframlag í söguna, skatole, sem óbein áhrif. Árásargjarn og kynferðisleg (uppbyggjandi) hegðun er einnig minni. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Firmagon Европейский союз - исландский - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Degarelix Accord Европейский союз - исландский - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.